Millward, M <br/><br/>
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.  [electronic resource] 

 -  British journal of cancer  May 2013 
 - 1998-2004 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2013.227  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Disease Progression<br/>Female<br/>Humans<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Oligodeoxyribonucleotides--administration & dosage<br/>Skin Neoplasms--drug therapy<br/>Treatment Outcome<br/>Young Adult